Enanta Pharmaceuticals (ENTA) Earnings Date & Reports

Key Takeaways

• Enanta Pharmaceuticals (ENTA) is scheduled to report results for its fiscal fourth quarter and full year ended September 30, 2026, with an estimated release date of November 16, 2026.
• Wall Street consensus points to a net loss of roughly $0.77 per share, with individual estimates ranging from about $0.55 to $0.95 per share.
• Consensus revenue sits near $14.5 million, driven almost entirely by royalties on AbbVie's hepatitis C treatment MAVYRET/MAVIRET.
• Investors will be closely watching for topline data from the Phase 1 trial of EDP-978, the company's oral KIT inhibitor for chronic urticaria.
• A pending Federal Circuit decision in Enanta's patent litigation against Pfizer over its COVID-19 antiviral PAXLOVID is a key event risk heading into the report.

Earnings Context and Why It Matters

Enanta Pharmaceuticals is a clinical-stage biotechnology company that funds its research and development largely through royalty revenue tied to AbbVie's hepatitis C virus (HCV) franchise, led by MAVYRET/MAVIRET. With no internally approved products yet, the company's quarterly results offer investors a window into both its financial runway and its maturing pipeline in respiratory syncytial virus (RSV) and immunology. This report matters because it caps a fiscal year in which Enanta advanced multiple early-stage immunology assets while managing a narrowing net loss. For a company whose near-term value hinges on clinical data readouts rather than product sales, the fiscal fourth quarter update is as much a pipeline progress check as a financial one.

Earnings Expectations

Analysts expect Enanta to report a net loss of approximately $0.77 per share for the fiscal fourth quarter, with estimates spanning roughly $0.55 to $0.95 per share depending on the source. Revenue is projected near $14.5 million, essentially all of it stemming from royalty payments on AbbVie's MAVYRET/MAVIRET sales for hepatitis C. For context, the company posted revenue of $14.36 million and a loss of $0.67 per share in the fiscal third quarter ended June 30, 2026, missing consensus on both lines. In the year-ago fourth quarter, Enanta recorded revenue of $15.13 million and a loss of $0.87 per share.

Because Enanta does not provide formal quarterly revenue or earnings-per-share guidance, investors will rely primarily on management's commentary regarding its cash runway, which the company has previously said extends into fiscal 2029. Key non-financial metrics to watch include clinical trial progress, research and development (R&D) expense trends, and any update to the timing of program milestones.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help surface trade ideas, trending stocks, breakout candidates, and broader market opportunities more efficiently than manual screening. For those tracking biotechnology names like Enanta Pharmaceuticals alongside peer RSV and immunology developers, the AI Screener offers a structured way to monitor emerging technical and fundamental setups.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautious. Enanta's shares have been volatile as the market weighs the company's clinical catalysts against its ongoing net losses and dependence on royalty income. The fiscal third quarter print, which missed both consensus revenue and earnings-per-share estimates, underscored how sensitive the stock is to short-term royalty fluctuations even as longer-term value rests on the pipeline. Heading into the fiscal fourth quarter release, investors are focused less on the income statement and more on qualitative updates: the anticipated Phase 1 data for EDP-978 and any regulatory clarity on the RSV program zelicapavir. A Federal Circuit ruling in the Pfizer patent case, expected around the end of September 2026, also carries the potential to move the stock independently of the financial results.

Forward Outlook and Key Factors to Monitor

The most important catalyst tied to this earnings cycle is the topline data from the Phase 1 trial of EDP-978, Enanta's once-daily oral KIT inhibitor (a drug targeting a receptor involved in mast cell-driven inflammatory conditions) being developed for chronic urticaria. The company has guided to reporting these results in the fiscal fourth quarter, making the accompanying earnings call a likely venue for an update.

Investors should also monitor progress on zelicapavir, Enanta's lead RSV candidate, where the company has been conducting enabling activities for a pivotal study in high-risk adults. Any update on study design or a registrational development path would be significant. Separately, Enanta has targeted an Investigational New Drug (IND) filing for EPS-3903, its oral STAT6 inhibitor (a molecule targeting a signaling protein linked to type 2 inflammatory diseases), in the second half of 2026.

From a financial standpoint, royalty revenue from AbbVie's MAVYRET/MAVIRET remains the company's lifeblood, and a portion of those royalties is contractually directed to OMERS under a prior royalty monetization agreement. Trend lines in R&D and general and administrative spending, along with the company's cash balance, will signal how comfortably Enanta can fund its pipeline into fiscal 2029. Finally, the outcome of the Pfizer PAXLOVID patent appeal could materially affect both the company's balance sheet and investor perception of its intellectual property position.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations